|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
1997-6-3
|
|
pubmed:abstractText |
The impact of amiodarone on mortality in patients with severe congestive heart failure (CHF) (New York Heart Association functional classes II [advanced], III and IV; left ventricular ejection fraction < 35%) In the Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA) trial was analyzed in relation to initial mean baseline heart rate (BHR) and its change after 6 months of follow-up.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0735-1097
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
29
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1199-205
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:9137213-Amiodarone,
pubmed-meshheading:9137213-Anti-Arrhythmia Agents,
pubmed-meshheading:9137213-Death, Sudden, Cardiac,
pubmed-meshheading:9137213-Female,
pubmed-meshheading:9137213-Follow-Up Studies,
pubmed-meshheading:9137213-Heart Failure,
pubmed-meshheading:9137213-Heart Rate,
pubmed-meshheading:9137213-Humans,
pubmed-meshheading:9137213-Life Tables,
pubmed-meshheading:9137213-Male,
pubmed-meshheading:9137213-Middle Aged,
pubmed-meshheading:9137213-Patient Selection,
pubmed-meshheading:9137213-Prospective Studies,
pubmed-meshheading:9137213-Survival Analysis,
pubmed-meshheading:9137213-Time Factors
|
|
pubmed:year |
1997
|
|
pubmed:articleTitle |
Heart rate is a marker of amiodarone mortality reduction in severe heart failure. The GESICA-GEMA Investigators. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina-Grupo de Estudios Multicéntricos en Argentina.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Multicenter Study
|
